Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders.

Lee SH, Kim BK, Oh J, Park JS, Lee DJ, Lee HC, Kim JH, Hong MK.

Korean Circ J. 2013 May;43(5):343-6. doi: 10.4070/kcj.2013.43.5.343. Epub 2013 May 31.


Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.

Kim YS, Lee SR.

Tex Heart Inst J. 2015 Oct 1;42(5):483-6. doi: 10.14503/THIJ-14-4491. eCollection 2015 Oct.


Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).

Valenti R, Marcucci R, Comito V, Marrani M, Cantini G, Migliorini A, Parodi G, Gensini GF, Abbate R, Antoniucci D.

JACC Cardiovasc Interv. 2015 Oct;8(12):1563-70. doi: 10.1016/j.jcin.2015.07.010. Epub 2015 Sep 17.


[Optimal platelet inhibition after coronary stent implantation. Current status].

Silber S, Hoffmeister HM, Bode C.

Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9. Review. German.


Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM; TRITON-TIMI 38 Investigators.

Lancet. 2008 Apr 19;371(9621):1353-63. doi: 10.1016/S0140-6736(08)60422-5. Epub 2008 Apr 2.


Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D.

J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7. Epub 2007 Jun 4.


Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D.

J Am Coll Cardiol. 2008 Aug 26;52(9):734-9. doi: 10.1016/j.jacc.2008.05.032.


Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.

Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ.

JACC Cardiovasc Interv. 2008 Oct;1(5):494-503. doi: 10.1016/j.jcin.2008.06.011.


A novel regimen of alternate day clopidogrel would provide a cost-effective strategy to prevent very late stent thrombosis.

Sharma S, Forrester JS.

Med Hypotheses. 2012 Jan;78(1):166-70. doi: 10.1016/j.mehy.2011.10.018. Epub 2011 Nov 8.


Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A.

J Am Coll Cardiol. 2013 May 21;61(20):2060-6. doi: 10.1016/j.jacc.2013.02.036. Epub 2013 Mar 21.


Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators.

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.


Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.

Migliorini A, Valenti R, Parodi G, Marcucci R, Abbate R, Carrabba N, Gensini GF, Antoniucci D.

Am J Cardiol. 2013 Dec 15;112(12):1843-8. doi: 10.1016/j.amjcard.2013.08.009. Epub 2013 Sep 21.


Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.

Pinto Slottow TL, Bonello L, Gavini R, Beauzile P, Sushinsky SJ, Scheinowitz M, Kaneshige K, Xue Z, Torguson R, Tantry U, Pichard AD, Satler LF, Suddath WO, Kent K, Gurbel P, Waksman R.

Am J Cardiol. 2009 Aug 15;104(4):525-30. doi: 10.1016/j.amjcard.2009.04.015. Epub 2009 Jun 24.


Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.

Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ, ten Berg JM, Schömig A, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators.

Am Heart J. 2009 Apr;157(4):620-4.e2. doi: 10.1016/j.ahj.2008.12.019.


Switching from clopidogrel to prasugrel in patients having coronary stent implantation.

Parodi G, De Luca G, Bellandi B, Comito V, Valenti R, Marcucci R, Carrabba N, Migliorini A, Ramazzotti RN, Gensini GF, Abbate R, Antoniucci D.

J Thromb Thrombolysis. 2014 Oct;38(3):395-401.


Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.

Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.


Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

Parodi G, Bellandi B, Venditti F, Carrabba N, Valenti R, Migliorini A, Grassellini S, Ramazzotti E, Antoniucci D.

Am J Cardiol. 2012 Jan 15;109(2):214-8. doi: 10.1016/j.amjcard.2011.08.034. Epub 2011 Oct 12.


Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A.

JAMA. 2005 May 4;293(17):2126-30.


"Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation.

Kaliyadan A, Siu H, Fischman DL, Ruggiero NJ 2nd, Jasti B, Walinsky P, Ogilby JD, Savage MP.

J Invasive Cardiol. 2014 Sep;26(9):413-6.

Supplemental Content

Support Center